Search

The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI). 641 patients who met the inclusion criteria were divided into two groups based on the receipt of either ticagrelor or clopidogrel based DAPT. Left ventricular thrombus was detected in 73 (11.4%) patients at the first month echocardiographic examination. Ticagrelor based DAPT was associated with significantly less incidence of LV thrombus when compared to clopidogrel [20 (7.4%) vs 53 (14.0%) OR: 0.50 (0.29–0.86)]. Penalized maximum likelihood estimation (PMLE) logistic regression analyses were performed to fourteen candidate variables for identifying the independent predictors of LV thrombus, ticagrelor (compared with clopidogrel) [OR: 0.53 (0.28–0.96), p = 0.039], body mass index (BMI) [OR: 0.58 (0.44–0.77), p < 0.001], KILLIP class (I vs II–IV) [OR: 0.35 (0.14–0.83), p = 0.017], age [OR: 1.22 (1.08–1.40), p < 0.001], poor postprocedural myocardial blush grade (MBG) [OR: 3.35 (1.32–8.15), p = 0.012] and LVEF predischarge [OR: 0.79 (0.72–0.86), p < 0.001] were found to be associated with LV thrombus. Our study demonstrated that the incidence of LV trombus was significantly lower with ticagrelor than clopidogrel-based DAPT during postdischarge treatment for anterior STEMI patients. • Left ventricular thrombus is a potential source of systemic embolization after STEMI. • Prophylactic treatment in addition to DAPT is not recommended after discharge. • Ticagrelor has faster and achieves more consistent P2Y12 inhibition than clopidogrel. • The incidence of left ventricular thrombus is lower with ticagrelor than clopidogrel. [ABSTRACT FROM AUTHOR]